Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05186974 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Study acronym: EVOKE-02
StatusActive, Not Recruiting
PhasePhase 2
Started2022-05-30
View on ClinicalTrials.gov ↗
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).

Amendment history 2 changes detected by DataLookout

2026-09-12
Primary completion pushed: 2026-09 → 2027-03
2026-09-12
Completion pushed: 2026-09 → 2027-03
Trial Details
NCT Number NCT05186974
Lead Sponsor Gilead Sciences
Collaborators: Merck Sharp & Dohme LLC
Conditions Non-small Cell Lung Cancer
Enrollment 193 participants
Start Date 2022-05-30
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-11